Biogen and Eisai to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab
SCHLIEREN / ZURICH, SWITZERLAND – March 21, 2019 – Neurimmune today informed that Biogen and Eisai decided to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab in Alzheimer’s disease. Neurimmune has partnered Aducanumab with Biogen in 2007. The independent data monitoring committee advised that the trials were unlikely to meet their primary endpoint upon completion. This recommendation was not based on safety concerns.
“This outcome is very disappointing for patients with Alzheimer’s disease and their families as well as for the entire Neurimmune team”, said Roger Nitsch, Neurimmune’s CEO & President. “Despite this setback in the quest for a cure for Alzheimer’s disease, Neurimmune remains committed to find solutions for neurodegenerative and other severe diseases.”
Neurimmune’s preclinical and clinical pipeline includes drug candidates at various development stages for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, cardiomyopathy, type 2 diabetes, as well as programs in cognitive dysfunction and attention disorders. Neurimmune’s R&D programs are based on its unique reverse translational medicine technology which enables the translation of DNA from human immune cells into next-generation antibodies.”